Replies to post #1 on Bioniche Life Science (BNHLF)

[BioSpecialist]

This stock is ready to takeoff ..


Strong buy for Bioniche

http://www.nasd100.com/2010/08/bestrated-canadian-stocks-aug-1-2010.html

Top 100 Strong Buy Canadian stocks for August 1, 2010
Below are the top 100 Strong Buy Canadian stocks based on average Wall Street analyst ratings. Each analyst rating is assigned a number ranging from 1 to 5, with 1 being the highest rating (STRONG BUY) and 5 being the lowest rating (STRONG SELL). The average is calculated to represent the overall rating of a stock.

Ranking | Company | Average Rating Value | Average Rating

1 AlarmForce Industries (TSE:AF) 1.00 Strong Buy
2 Altius Minerals Corporation (TSE:ALS) 1.00 Strong Buy
3 Amorfix Life Sciences Ltd. (TSE:AMF) 1.00 Strong Buy
4 Aquila Resources Inc. (TSE:AQA) 1.00 Strong Buy
5 Aeroquest International Limited (TSE:AQL) 1.00 Strong Buy
6 Bioniche Life Sciences (TSE:BNC) 1.00 Strong Buy <<<<<<<<<<<<<<<<<

[peterus]

hello,when will they get approval fda fase 3

[BioSpecialist]

LAST CHANCE TO GET IN CHEAP !

BNC HITS NEW 2 YEAR-HIGH TODAY = MAJOR BREAKOUT COMING
http://www.barchart.com/chart.php?sym=BNC.TO&style=technical&p=DO&d=O&sd=&ed=&size=M&log=0&t=CANDLE&v=1&g=1&evnt=1&late=1&o1=&o2=&o3=&x=28&y=9&sh=100&indicators=SMA%28200%2C16711680%29&chartindicator_2_code=SMA&chartindicator_2_param_0=200&chartindicator_2_param_1=16711680&addindicator=&submitted=1&fpage=&txtDate=#jump



Market cap of 90 M$ is wayyyyyyy undervalued .

Urocidin (Bladder Cancer) Phase 3 results in September (VERY LOW RISK ) . Only 105 Patients in current Phase 3 .Check out the POSITIVE Phase2 results from 2008 involving 128 Patients (see post below) !!!!


TWST: Give us more detail on that pipeline. What is near term and what is a little longer term?


Mr. McRae: The primary technology is called Mycobacterial Cell Wall-DNA Complex, and it sounds like a mouthful but really we found a naturally occurring bacteria where the DNA of the bacteria had a very unusual property ' it can actually kill cancer cells. It kills cancer cells in the face of mutations that would normally stop chemotherapy or radiation therapy from being effective. [B]This DNA is quite unique in that the tumor cells, even when they try to mutate around it, are unable to induce resistance to this compound; and it's extremely safe. We have a 70% complete response rate in patients who failed other therapies, so our Phase II data, which is in the public domain, shows about 128 patients with an average complete response of about 70%. These are patients who at the end of the study were disease-free and had really no side effects worth noting due to the product.[/B] The patients were able to maintain treatment, whereas without the treatments they drop out because of side effects, so that is our primary technology. It has been shown effective in-vitro in the lab against many different types of cancer. In fact, we can't find a cancer cell it doesn't kill. But in our clinical plan, it is bladder cancer first and prostate cancer second. In prostate cancer, we have completed a Phase I study